JAVELIN Merkel 200: Results of Phase II Study for Merkel Cell Carcinoma

JAVELIN Merkel 200: Results of Phase II Study for Merkel Cell Carcinoma

User Photo
aacr2017

3 years
1,876 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey gives an overview of his current research, a phase II study which involved a newly FDA-approved drug, avelumab, in patients with merkel cell carcinoma. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Up Next Autoplay
>